These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 10847471)

  • 21. Treatment of metastatic malignant melanoma with dacarbazine, vindesine and cisplatin.
    Pectasides D; Yianniotis H; Alevizakos N; Bafaloukos D; Barbounis V; Varthalitis J; Dimitriadis M; Athanassiou A
    Br J Cancer; 1989 Oct; 60(4):627-9. PubMed ID: 2803936
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of advanced malignant melanoma with interferon alpha and etretinate.
    Rustin GJ; Dische S; de Garis ST; Nelstrop A
    Eur J Cancer Clin Oncol; 1988 Apr; 24(4):783-4. PubMed ID: 3383979
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dacarbazine, vindesine, and cisplatin combination chemotherapy in advanced malignant melanoma: a phase II study.
    Gundersen S
    Cancer Treat Rep; 1987 Nov; 71(11):997-9. PubMed ID: 3677119
    [No Abstract]   [Full Text] [Related]  

  • 24. Successful treatment of metastatic malignant melanoma with Viscum album extract (Iscador M).
    Kirsch A
    J Altern Complement Med; 2007 May; 13(4):443-5. PubMed ID: 17532738
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Three consecutive phase II studies of recombinant interferon alfa-2a in advanced malignant melanoma. Updated analyses.
    Creagan ET; Ahmann DL; Frytak S; Long HJ; Chang MN; Itri LM
    Cancer; 1987 Feb; 59(3 Suppl):638-46. PubMed ID: 10822463
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Metastatic malignant melanoma of the urinary bladder: a case report].
    Nohara T; Sakai A; Fuse H; Imamura Y
    Nihon Hinyokika Gakkai Zasshi; 2009 Nov; 100(7):707-11. PubMed ID: 19999137
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multi-institutional phase II randomized trial of integrated therapy with cisplatin, dacarbazine, vindesine, subcutaneous interleukin-2, interferon alpha2a and tamoxifen in metastatic melanoma. BREMIM (Biological Response Modifiers in Melanoma).
    Sertoli MR; Queirolo P; Bajetta E; Del Vecchio M; Comella G; Barduagni L; Bernengo MG; Vecchio S; Criscuolo D; Bufalino R; Morabito A; Cascinelli N
    Melanoma Res; 1999 Oct; 9(5):503-9. PubMed ID: 10596917
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The use of BELD combination chemotherapy (bleomycin, vindesine, CCNU, and DTIC) in advanced malignant melanoma.
    Young DW; Lever RS; English JS; MacKie RM
    Cancer; 1985 May; 55(9):1879-81. PubMed ID: 2579722
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma.
    Grob JJ; Dreno B; de la Salmonière P; Delaunay M; Cupissol D; Guillot B; Souteyrand P; Sassolas B; Cesarini JP; Lionnet S; Lok C; Chastang C; Bonerandi JJ
    Lancet; 1998 Jun; 351(9120):1905-10. PubMed ID: 9654256
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [A case of malignant melanoma from the esophagus responding to weekly paclitaxel therapy].
    Kakudo Y; Yoshioka T; Noguchi S; Hanada M; Otsuka K; Sakayori M; Chiba N; Shibata H; Kato S; Shimodaira H; Ohori H; Takahashi S; Takahashi M; Yamaura G; Yasuda K; Ishioka C
    Gan To Kagaku Ryoho; 2006 Jul; 33(7):969-72. PubMed ID: 16835489
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen, or vindesine plus tamoxifen: a prospective randomized study.
    Cocconi G; Passalacqua R; Foladore S; Carlini P; Acito L; Maiello E; Marchi M; Gebbia V; Di Sarra S; Beretta M; Bacchi M
    Melanoma Res; 2003 Feb; 13(1):73-9. PubMed ID: 12569288
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination chemotherapy with dacarbazine and vindesine in the treatment of metastatic malignant melanoma.
    Vorobiof DA; Sarli R; Falkson G
    Cancer Treat Rep; 1986 Jul; 70(7):927-8. PubMed ID: 3719588
    [No Abstract]   [Full Text] [Related]  

  • 33. Adjuvant chemotherapy with dacarbazine, vindesine, and cisplatin in pathological stage II malignant melanoma.
    Pectasides D; Alevizakos N; Bafaloukos D; Tzonou A; Asimakopoulos G; Varthalitis I; Dimitriadis M; Athanassiou A
    Am J Clin Oncol; 1994 Feb; 17(1):55-9. PubMed ID: 8311008
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.
    Hancock BW; Wheatley K; Harris S; Ives N; Harrison G; Horsman JM; Middleton MR; Thatcher N; Lorigan PC; Marsden JR; Burrows L; Gore M
    J Clin Oncol; 2004 Jan; 22(1):53-61. PubMed ID: 14665609
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Brain metastases following interleukin-2 plus interferon-alpha-2a therapy: a follow-up study in 94 stage IV melanoma patients.
    Schmittel A; Proebstle T; Engenhart-Cabillic R; Scheibenbogen C; Geueke AM; Thiel E; Keilholz U
    Eur J Cancer; 2003 Mar; 39(4):476-80. PubMed ID: 12751378
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metastatic melanoma of the vulva identified by peritoneal fluid cytology.
    Izban KF; Candel AG; Hsi ED; Selvaggi SM
    Diagn Cytopathol; 1999 Mar; 20(3):152-5. PubMed ID: 10086239
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma.
    Verma S; Quirt I; McCready D; Bak K; Charette M; Iscoe N
    Cancer; 2006 Apr; 106(7):1431-42. PubMed ID: 16511841
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adjuvant therapy of malignant melanoma and the role of sentinel node mapping.
    Eggermont AM
    Recent Results Cancer Res; 2000; 157():178-89. PubMed ID: 10857171
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Complete response in a patient with a metastatic cutaneous melanoma].
    Bermejo-Pérez MJ; Villar-Chamorro E; Lemos-Simosomo M; García-González C; Galeote-Miguel AM
    An Sist Sanit Navar; 2011; 34(2):307-10. PubMed ID: 21904414
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prospective randomized trial in advanced malignant melanoma with cis-platinum, vindesine, and etoposide vs. cis-platinum, vindesine, and lomustine.
    Bajetta E; Buzzoni R; Viviani S; Vaglini M; Nava M; Bonadonna G
    Am J Clin Oncol; 1985 Oct; 8(5):401-5. PubMed ID: 3904398
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.